Completed PHASE4 INTERVENTIONAL 1-arm NCT01521975

A Two-year Study of Telbivudine in HBeAg Negative Hepatitis (STEN)

A Two-year, Open-label, Virological Response Adaptive Design, Multicenter Study to Evaluate Efficacy of Telbivudine in HBeAg Negative Adult CHB Patients With Roadmap Strategy

Sponsor: Guangdong Provincial People's Hospital

Conditions Hepatitis B, Chronic

Interventions Telbivudine, Adefovir dipivoxil

Updated 7 times since 2017 Last updated: Oct 22, 2017 Started: Jan 1, 2011 Primary completion: Feb 28, 2014 Completion: May 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Hepatitis B, Chronic and is currently completed. Guangdong Provincial People's Hospital leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Nov 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Feb 2017 — Nov 2017 [monthly]

Unknown Status PHASE4
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangdong Provincial People's Hospital
Guangzhou 8th People's Hospital
Third Affiliated Hospital, Sun Yat-Sen University

Data source: Third Affiliated Hospital, Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China